HER-2/neu assessment for gastric carcinoma: Validation of scoring system

Hepato-Gastroenterology

Volumn 59, Issue 113, 2012, Pages 300-303

  Mrklic, Ivana ^a   Bendic, Antonia ^a   Kunac, Nenad ^a   Bezic, Josko ^a   Forempoher, Gea ^a   Durdov, Merica Glavina ^a   Karaman, Ivana ^a   Prusac, Ivana Kuzmic ^a   Pisac, Valdi Pesutic ^a   Vilovic, Katarina ^a   Tomic, Snjezana ^a  

^a UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Gastric cancer; HER 2 neu; Validation study

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENOMIC IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONCOGENE; PATHOLOGIST; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH BIOPSY; STOMACH CARCINOMA; VALIDATION STUDY;

BIOPSY; CARCINOMA; CROATIA; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84858194949     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10776     Document Type: Article

References (23)

1. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56:1-9. (Pubitemid 36183309)
2. Garvalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523-1529.
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erb-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1644-1646. (Pubitemid 16095607)
4. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto oncogene in human breast and ovarian cancer. Science 1989; 244:707-12. (Pubitemid 19147683)
5. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E: HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001; 12:15-19.
6. Scholl S, Beuzeboc P, Pouillart P: Targeting HER2 in other tumor types. Ann Oncol 2001; 12:81-87.
7. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, Kuroki T, Kano K: Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.J Natl Cancer Inst 1986; 77:1047-52. (Pubitemid 17184126)
8. Bang YJ, Chung HC, Sawaki A, Xu JM, Shen L, Lipatov O, Park SR, Gangadharan VP, Advani S, Kang YK: HER2- positivity rates in advanced gastric cancer: results from a large international Phase III trial. 2009 ASCO Annual Meeting.
9. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59:795-805. (Pubitemid 46440603)
10. Hofman M, Stoss O, Shi D, Büttner R, Van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T: Assessment of a HER 2 scoring system for gastric cancer: results from a validation study. Histopathol 2008; 52:797-805. (Pubitemid 351724903)
11. Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for Human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45. (Pubitemid 350003059)
12. Fleiss JL. Statistical methods for rates and proportions.Second edition.Wiley Series in probability and mathematical statistics, 2003.
13. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-74. (Pubitemid 8054849)
14. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S: Molecular biology of sporadic gastric cancer:prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30:451-459. (Pubitemid 38968125)
15. Garvalos C, Márquez A, Garciá-Carbonero R: Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium 2007 (Abstr 89).
16. Lin JT, Wu MS, Shun CT, Lee WJ, Sheu JC, Wang TH: Occurrence of microsatellite instabilty in gastrica carcinoma is associated with enhanced expression of erbB-2 oncoprotein. Cancer Res 1995; 55:1428-1430.
17. Wu MS, Shun CT, Wang HP Sheu JC, Lee WJ, Wang TH, Lin JT: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997; 112:1457-1465.
18. Polkowski W, Van Sancick JW, Offerhaus GL, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ: Prognostic value of Lauren's classification and c-erbB-2 oncogene overexpression in adenocarcinomaof the esophagus and gastroesophageal junction. Ann Surg Oncol 1999; 6:290-297. (Pubitemid 29221016)
19. Lemoine NR, Jain S, Silvestre F, et al.: Amplification and overexpression of the EGF receptor and c-erbB-2 proto- oncogenes in human stomac cancer. Br J Cancer 1991; 64:79-83.
20. Tanner M, Hollmen M, Junttila TT, et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273-278. (Pubitemid 40309309)
21. Lordick F, Bang YJ, Kang YK: HER2-positive advanced gastic cancer: similar HER2- positivity levels to breast cancer. Eur J Cancer 2007; 5:271.
22. Tamanory Y, Toshihiko D, Atsushi O, Narikazu B, Kaoru H, Mamoru N and Atsushi O: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridisation and HER2 protein expression assessed by immunohistochemistry in gastic cancer. Oncology Reports 2006; 15:65-71.
23. Rüschoff J, Dietel M, Baretton G, et al.: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457(3):299-307.